WallStreetZenWallStreetZen

NASDAQ: REGN
Regeneron Pharmaceuticals Inc Stock

$742.83+0.53 (+0.07%)
Updated Jan 27, 2023
REGN Price
$742.83
Fair Value Price
$773.25
Market Cap
$80.90B
52 Week Low
$538.01
52 Week High
$779.00
P/E
14.77x
P/B
3.77x
P/S
5.37x
PEG
N/A
Dividend Yield
N/A
Revenue
$13.71B
Earnings
$5.37B
Gross Margin
85.4%
Operating Margin
44.45%
Profit Margin
39.2%
Debt to Equity
0.29
Operating Cash Flow
$6B
Beta
0.67
Next Earnings
Feb 3, 2023
Ex-Dividend
N/A
Next Dividend
N/A

REGN Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how REGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

REGN ($742.83) is undervalued by 3.93% relative to our estimate of its Fair Value price of $773.25 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
REGN ($742.83) is not significantly undervalued (3.93%) relative to our estimate of its Fair Value price of $773.25 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
REGN is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more REGN due diligence checks available for Premium users.

Be the first to know about important REGN news, forecast changes, insider trades & much more!

REGN News

Valuation

REGN fair value

Fair Value of REGN stock based on Discounted Cash Flow (DCF)
Price
$742.83
Fair Value
$773.25
Undervalued by
3.93%
REGN ($742.83) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
REGN ($742.83) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
REGN is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

REGN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
14.77x
Industry
12.89x
Market
23.59x
REGN is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
REGN is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

REGN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.77x
Industry
5.18x
REGN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

REGN's financial health

Profit margin

Revenue
$2.9B
Net Income
$1.3B
Profit Margin
44.8%
REGN's Earnings (EBIT) of $6.09B... subscribe to Premium to read more.
Interest Coverage Financials
REGN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$27.7B
Liabilities
$6.2B
Debt to equity
0.29
REGN's short-term assets ($15.43B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
REGN's short-term assets ($15.43B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
REGN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
REGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$628.9M
Investing
$192.3M
Financing
-$725.0M
REGN's operating cash flow ($5.67B)... subscribe to Premium to read more.
Debt Coverage Financials

REGN vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
REGN$80.90B+0.07%14.77x3.77x
VRTX$82.51B+0.13%25.11x6.33x
MRNA$72.74B-2.01%6.45x4.04x
BNTX$34.91B+0.79%3.46x1.94x
ALNY$28.47B-0.09%-23.68x-420.84x

Regeneron Pharmaceuticals Stock FAQ

What is Regeneron Pharmaceuticals's quote symbol?

NASDAQ: REGN) Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol REGN. Regeneron Pharmaceuticals stock quotes can also be displayed as NASDAQ: REGN.

If you're new to stock investing, here's how to buy Regeneron Pharmaceuticals stock.

What is the 52 week high and low for Regeneron Pharmaceuticals (NASDAQ: REGN)?

(NASDAQ: REGN) Regeneron Pharmaceuticals's 52-week high was $779.00, and its 52-week low was $538.01. It is currently -4.64% from its 52-week high and 38.07% from its 52-week low.

How much is Regeneron Pharmaceuticals stock worth today?

(NASDAQ: REGN) Regeneron Pharmaceuticals currently has 108,901,935 outstanding shares. With Regeneron Pharmaceuticals stock trading at $742.83 per share, the total value of Regeneron Pharmaceuticals stock (market capitalization) is $80.90B.

Regeneron Pharmaceuticals stock was originally listed at a price of $8.56 in Dec 31, 1997. If you had invested in Regeneron Pharmaceuticals stock at $8.56, your return over the last 25 years would have been 8,574.88%, for an annualized return of 19.54% (not including any dividends or dividend reinvestments).

How much is Regeneron Pharmaceuticals's stock price per share?

(NASDAQ: REGN) Regeneron Pharmaceuticals stock price per share is $742.83 today (as of Jan 27, 2023).

What is Regeneron Pharmaceuticals's Market Cap?

(NASDAQ: REGN) Regeneron Pharmaceuticals's market cap is $80.90B, as of Jan 30, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Regeneron Pharmaceuticals's market cap is calculated by multiplying REGN's current stock price of $742.83 by REGN's total outstanding shares of 108,901,935.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.